A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT04272957
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
HMPL-306
Sponsor
Hutchison Medipharma Limited